Cargando…

Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis

Objective: Symptomatic in-stent restenosis (sISR) is the major cause of medium- or long-term cerebral infarctions in patients who underwent percutaneous transluminal angioplasty and stenting for severe intracranial atherosclerotic stenosis. This study aims to evaluate the feasibility and safety of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haowen, Fu, Xiaojie, Yuan, Yongjie, Quan, Tao, Wang, Zibo, Han, Kaihao, Liu, Guo, Guan, Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431892/
https://www.ncbi.nlm.nih.gov/pubmed/32849227
http://dx.doi.org/10.3389/fneur.2020.00774
_version_ 1783571674019397632
author Xu, Haowen
Fu, Xiaojie
Yuan, Yongjie
Quan, Tao
Wang, Zibo
Han, Kaihao
Liu, Guo
Guan, Sheng
author_facet Xu, Haowen
Fu, Xiaojie
Yuan, Yongjie
Quan, Tao
Wang, Zibo
Han, Kaihao
Liu, Guo
Guan, Sheng
author_sort Xu, Haowen
collection PubMed
description Objective: Symptomatic in-stent restenosis (sISR) is the major cause of medium- or long-term cerebral infarctions in patients who underwent percutaneous transluminal angioplasty and stenting for severe intracranial atherosclerotic stenosis. This study aims to evaluate the feasibility and safety of paclitaxel-coated balloon (PCB) angioplasty for the treatment of intracranial sISR. Methods: We report 11 cases of PCB angioplasty for intracranial sISR. Lesion locations and number were as follows: intracranial internal carotid artery (n = 4), M1 segment of middle cerebral artery (MCA) (n = 1), V4 segment of vertebral artery (n = 6). The technical success rate, periprocedural complications, and short-term outcome were retrospectively analyzed. Results: All procedures were successfully performed without periprocedural complication. Asymptomatic vessel dissection after PCB inflation occurred in one case. Postprocedural diffusion-weighted imaging (DWI) showed new asymptomatic ipsilateral infarction in one case. All 11 cases did not experience ipsilateral stroke or death within 30 days or ischemic stroke in the territory of the target artery between 31 and 90 days after procedure. Conclusion: This preliminary study indicates that PCB angioplasty is feasible and safe for the treatment of intracranial sISR. Further studies are needed to clarify its efficiency and long-term outcome.
format Online
Article
Text
id pubmed-7431892
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74318922020-08-25 Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis Xu, Haowen Fu, Xiaojie Yuan, Yongjie Quan, Tao Wang, Zibo Han, Kaihao Liu, Guo Guan, Sheng Front Neurol Neurology Objective: Symptomatic in-stent restenosis (sISR) is the major cause of medium- or long-term cerebral infarctions in patients who underwent percutaneous transluminal angioplasty and stenting for severe intracranial atherosclerotic stenosis. This study aims to evaluate the feasibility and safety of paclitaxel-coated balloon (PCB) angioplasty for the treatment of intracranial sISR. Methods: We report 11 cases of PCB angioplasty for intracranial sISR. Lesion locations and number were as follows: intracranial internal carotid artery (n = 4), M1 segment of middle cerebral artery (MCA) (n = 1), V4 segment of vertebral artery (n = 6). The technical success rate, periprocedural complications, and short-term outcome were retrospectively analyzed. Results: All procedures were successfully performed without periprocedural complication. Asymptomatic vessel dissection after PCB inflation occurred in one case. Postprocedural diffusion-weighted imaging (DWI) showed new asymptomatic ipsilateral infarction in one case. All 11 cases did not experience ipsilateral stroke or death within 30 days or ischemic stroke in the territory of the target artery between 31 and 90 days after procedure. Conclusion: This preliminary study indicates that PCB angioplasty is feasible and safe for the treatment of intracranial sISR. Further studies are needed to clarify its efficiency and long-term outcome. Frontiers Media S.A. 2020-08-11 /pmc/articles/PMC7431892/ /pubmed/32849227 http://dx.doi.org/10.3389/fneur.2020.00774 Text en Copyright © 2020 Xu, Fu, Yuan, Quan, Wang, Han, Liu and Guan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Xu, Haowen
Fu, Xiaojie
Yuan, Yongjie
Quan, Tao
Wang, Zibo
Han, Kaihao
Liu, Guo
Guan, Sheng
Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis
title Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis
title_full Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis
title_fullStr Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis
title_full_unstemmed Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis
title_short Feasibility and Safety of Paclitaxel-Coated Balloon Angioplasty for the Treatment of Intracranial Symptomatic In-Stent Restenosis
title_sort feasibility and safety of paclitaxel-coated balloon angioplasty for the treatment of intracranial symptomatic in-stent restenosis
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431892/
https://www.ncbi.nlm.nih.gov/pubmed/32849227
http://dx.doi.org/10.3389/fneur.2020.00774
work_keys_str_mv AT xuhaowen feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT fuxiaojie feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT yuanyongjie feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT quantao feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT wangzibo feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT hankaihao feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT liuguo feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis
AT guansheng feasibilityandsafetyofpaclitaxelcoatedballoonangioplastyforthetreatmentofintracranialsymptomaticinstentrestenosis